Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Trigen previously announced the successful completion of a Phase I dose escalation study on TGN 167 using a classical rapid release tablet formulation. Trigen is developing TGN 167 for safe, effective, predictable and convenient anticoagulation for chronic out-patient use in the prevention and treatment of thrombosis. Trigen is a private UK biotechnology company, based in London, that discovers and develops novel drugs for the management of occlusive and inflammatory cardiovascular diseases. Trigen’s lead programme, comprising a series of anticoagulant direct thrombin inhibitors (DTIs) for the prevention and treatment of thrombosis, is in clinical development in both intravenous and oral ( www.trigen.co.uk )
Trigen Ltd
Clareville House 26-27 Oxendon Street
London SW1Y 4EL
United Kingdom
Tel: +44 20 7004 2630
Fax: +44 20 7004 2631